Fundraising Fox
Olatec Therapeutics
New York, US · 2 known investors
Find your way into Olatec Therapeutics
Sign up to find every way you can get introduced to Olatec Therapeutics
- Your email: who you already know at Olatec Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Olatec Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.
Founders & leadership
Investors · 2
Also in the syndicate · 1
Sanders Morris Harrislead
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AFeb 2023
Sanders Morris Harris (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Olatec Therapeutics do?
- Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.
- Who founded Olatec Therapeutics?
- Olatec Therapeutics was founded by Damaris Skouras.
- Who are Olatec Therapeutics's investors?
- Olatec Therapeutics's investors include Advection Growth Capital.
- Where is Olatec Therapeutics headquartered?
- Olatec Therapeutics is headquartered in New York, US.